Article

Radiation Therapy in Youth Increases Risk of Breast Cancer

Girls who received mantle radiation for childhood cancer were found to be at elevated risk for secondary breast cancer later in life.

Girls who received mantle radiation for childhood cancer were found to be at elevated risk for secondary breast cancer later in life.

Although childhood cancers are typically treated with more moderate doses of radiation, new data presented at the American Society of Clinical Oncology (ASCO) annual meeting shows that having radiation therapy in childhood increases the risk of developing breast cancer later in life—and this risk was found to be approximately equal to the risk associated with women who have BRCA1 or BRCA2 mutations.

“While most women are aware that hereditary mutations can increase the risk for breast cancer, few are aware that radiation to the chest can also increase this risk, including the women who themselves were treated,” noted lead author Chaya Moskowitz, PhD, biostatistician, Memorial Sloan-Kettering Cancer Center, in a press release.

Dr. Moskowitz and colleagues analyzed data from 1268 cancer survivors in the Childhood Cancer Survivor Study and compared these results with 4570 first-degree female relatives of participants in the Women’s Environmental Cancer and Radiation Epidemiology study to estimate the incidence of breast cancer in these two populations.

The study revealed that breast cancer incidence by age 50 among women treated with chest radiation for childhood cancer was 24% compared to 31% for carriers of the BRCA1 mutations. For women exposed to high levels (20 Gy or more) of mantle radiation formerly used with Hodgkin lymphoma, the incidence of breast cancer was 30%.

Dr. Moskowitz noted that the dosage of radiation given in youth is not the only variable affecting breast cancer incidence. “The volume of breast tissue that is exposed to radiation is also a critical factor,” she added.

Based on the study’s findings, the authors recommend that women given whole-lung radiation in childhood, regardless of the dosage, should get regular breast cancer screenings starting at an early age.

The Children’s Oncology Group recommends the following monitoring for patients treated with chest radiation therapy during childhood, adolescence, or young adulthood:

  • Perform monthly breast self-examinations. Any lumps or changes to the breast should be reported to a healthcare provider right away.
  • Have a clinical breast exam performed by a health care provider at least once a year until age 25, and then every 6 months thereafter.
  • Have a yearly mammogram starting at age 25 or 8 years after receiving radiation (whichever comes last).

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards